About EOS Milano
EOS Milano is a company based in Milano (Italy) founded in 2005 was acquired by Clovis Oncology in November 2013. EOS Milano has raised $17.23 million across 2 funding rounds from investors including Sofinnova, Aescap and Principia SGR. EOS Milano operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Milano, Italy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.23 M (USD)
in 2 rounds
-
Latest Funding Round
$17.23 M (USD), Series A
Jul 30, 2009
-
Investors
Sofinnova
& 3 more
-
Employee Count
Not available
-
Acquired by
Clovis Oncology
(Nov 19, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of EOS Milano
EOS Milano has successfully raised a total of $17.23M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17.23 million completed in July 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EOS Milano
EOS Milano has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Sofinnova, Aescap and Principia SGR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences sector focused early stage VC firm investing primarily in Europe
|
Locked | Locked | Locked | |
|
Aescap is focused on investing in high-growth biotech companies.
|
Locked | Locked | Locked | |
|
Early-stage investments in Italian tech and life sciences are targeted.
|
Locked | Locked | Locked |
Investor details for EOS Milano
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EOS Milano
Investment portfolio details for EOS Milano
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EOS Milano
Detailed financials for EOS Milano
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eos Milano Comparisons
Peer comparison for EOS Milano
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EOS Milano
EOS Milano operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of EOS Milano
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eos Milano
Complete news archive for EOS Milano
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EOS Milano
EOS Milano was founded in 2005 and raised its 1st funding round 1 year after it was founded.
EOS Milano is headquartered in Milano, Italy.
EOS Milano is a funded company, having raised a total of $17.23M across 2 funding rounds to date.
Ethical Oncology Science (EOS) was founded in 2005 in Milano, Italy, as a biopharmaceutical company focused on oncology. Cancer treatments were advanced through the development of Lucitanib, an oral small-molecule tyrosine kinase inhibitor targeted at preventing new blood vessel formation in tumors and disrupting growth in FGF-dependent cancers. Phase III clinical trials were conducted for this compound. The company was acquired by Clovis Oncology in November 2013.
EOS Milano's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
EOS Milano has 4 investors. Key investors include Sofinnova, Aescap, Principia SGR, and Clovis Oncology.